CD8A and neoplasm: This was demonstrated by the identification of a brachyury 9-mer peptide that was used to expand human brachyury-specific CD8+ T cells from the blood of cancer patients in vitro which, in turn, were able to lyse brachyury-positive tumor cells in an MHC class I–restricted manner [5].